20 reports

Anti-PD-## Monoclonal Antibodies ##. ##. ##.

  • Ear, Nose, And Throat Medicine
  • Health Services
  • World
  • Market Size

Assessment Assessment Opdivo is a fully human IgG## monoclonal antibody.

  • Ear, Nose, And Throat Medicine
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Pfizer Inc.

Head and neck cancer

4385 5000 3900
  • Late-stage pipeline products in development for head and neck cancer
  • Erbitux drug profile

Keytruda is a fully humanized monoclonal antibody that inhibits the PD-## co-inhibitory receptor.

  • Ear, Nose, And Throat Medicine
  • United States
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
  • Head And Neck Cancer
  • Head And Neck Cancer Squamous Cell Carcinoma

Avelumab is a human anti-PD-L## IgG## monoclonal antibody.

  • Ear, Nose, And Throat Medicine
  • Medical Biotechnology
  • Sexually Transmitted Disease
  • Therapy
  • Inovio Pharmaceuticals, Inc.

With the development of less toxic, non-chemotherapy drugs for cancer treatment, such as targeted therapies like monoclonal antibody and small-molecule drugs, the need to use toxic chemotherapeutics may decline for certain cancers.

  • Ear, Nose, And Throat Medicine
  • Japan
  • United States
  • Amgen Inc.
  • Galenica Group

The drug candidate is a humanized monoclonal antibody.

  • Ear, Nose, And Throat Medicine
  • Therapy
  • United States
  • Company
  • Soligenix, Inc.

AUTO-IMMUNE INNER EAR DISEASE OCCURS WHEN ANTIBODIES OR IMMUNE CELLS START ATTACKING THE INNER EAR.

  • Ear, Nose, And Throat Medicine
  • United States
  • AudioCure Pharma GmbH
  • Autifony Therapeutics Limited
  • Cochlear Limited
  • Clinical Trial profile. 380 Trial Title
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Merck KG ## ## ## ## ## ## ## C.

  • Ear, Nose, And Throat Medicine
  • Monoclonal Antibody
  • United States
  • World
  • Product Initiative
  • 5. All the trials included are unique trials.

Merck KG ## ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## ## Merck & Co Inc ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## Bristol-Myers Squibb Co ## ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## ## Eli Lilly and Co ## ## ## ##

  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • Lung Cancer
  • World
  • Merck & Co., Inc.
  • 5. All the trials included are unique trials.

Boehringer Sohn AG & Co KG ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## Astellas Pharma Inc ## ## ## ## ## ## ## E.

  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • Monoclonal Antibody
  • World
  • Bristol-Myers Squibb Company

Aevi' s product candidate AEVI-##, is an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset Crohn' s disease.

  • Ear, Nose, And Throat Medicine
  • Neurological Disorder
  • World
  • Product Initiative
  • Addex Therapeutics Ltd

The prominent features of this report are - ##.

  • Ear, Nose, And Throat Medicine
  • Targeted Therapy
  • Therapy
  • World
  • Product Initiative
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Lee Moffitt Cancer Center & Research Institute Inc National Cancer Institute US ## Nov 2014 ## Jun 2014 ## Jul 2018 ## ## ## Official Title Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Typ

  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • Monoclonal Antibody
  • United States
  • World

KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-## About KEYTRUDA (pembrolizumab) Injection ##mg and its ligands, PD-L## and PD-L##, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.

  • Ear, Nose, And Throat Medicine
  • Germany
  • Southern Europe
  • Western Europe
  • Sonova Holding AG

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • Monoclonal Antibody
  • United States
  • World
  • HEAD AND NECK CANCER SQUAMOUS CELL CARCINOMA - PIPELINE BY KOLLTAN PHARMACEUTICALS, INC., H1 2016
  • HEAD AND NECK CANCER SQUAMOUS CELL CARCINOMA - PIPELINE BY SHANGHAI HENLIUS BIOTECH CO., LTD., H1 2016

The drug candidate is an anti- PD-L## monoclonal antibody, acts on CD## (Programmed Cell Death ##-Ligand ## or PDL-##).

  • Ear, Nose, And Throat Medicine
  • Monoclonal Antibody
  • United States
  • Company
  • Product Initiative
  • Clinical Trial profile. 343 Trial Title

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Drug Development
  • Ear, Nose, And Throat Medicine
  • Pharmaceutical
  • World
  • MONOCLONAL ANTIBODY TO TARGET CD147 FOR PANCREATIC ADENOCARCINOMA AND HEAD AND NECK CANCER SQUAMOUS CELL CARCINOMA - DRUG PROFILE
  • HEAD AND NECK CANCER SQUAMOUS CELL CARCINOMA - PIPELINE BY KOLLTAN PHARMACEUTICALS, INC., H2 2016

NIVOLUMAB (OPDIVO) IS A HUMAN IGG## ANTI-PD-## MONOCLONAL ANTIBODY.

  • Ear, Nose, And Throat Medicine
  • Monoclonal Antibody
  • United States
  • Company
  • Product Initiative
  • Head and Neck Cancer, Marketed Product Overview by Molecule Type and Mechanism of Action, 2016
  • Head and Neck Cancer, Co-development Deals by Molecule Type, 2006-2016

Erbitux is a chimeric monoclonal IgG## antibody that binds to EGFR and therefore blocks binding of ligands to EGFR, inhibiting receptor phosphorylation and downstream events such as activation of receptor-associated kinases (Kirkpatrick et al., 2004).

  • Cancer
  • Ear, Nose, And Throat Medicine
  • Health Services
  • Healthcare
  • Therapy
  • Clinical Trial Profile Snapshots

The prominent features of this report are - ##.

  • Ear, Nose, And Throat Medicine
  • Lung Cancer
  • Therapy
  • World
  • Product Initiative